Edition:
India

AzurRx BioPharma Inc (AZRX.OQ)

AZRX.OQ on NASDAQ Stock Exchange Capital Market

1.03USD
12:20am IST
Change (% chg)

$-0.02 (-1.90%)
Prev Close
$1.05
Open
$1.03
Day's High
$1.07
Day's Low
$1.00
Volume
147,265
Avg. Vol
39,934
52-wk High
$3.75
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

AzurRx BioPharma Announces Initiation Of Phase 2 Clinical Study For Ms1819-Sd
Tuesday, 9 Jul 2019 

July 8 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY FOR MS1819-SD IN COMBINATION WITH STANDARD PERT FOR CYSTIC FIBROSIS PATIENTS WITH SEVERE EXOCRINE PANCREATIC INSUFFICIENCY.AZURRX BIOPHARMA INC - PRELIMINARY DATA EXPECTED IN EARLY 2020..AZURRX BIOPHARMA INC - PRELIMINARY DATA EXPECTED IN EARLY 2020..  Full Article

Azurrx Files Prospectus Related To Possible Resale From Time To Time Of Up To 1.6 Million Shares
Friday, 26 Apr 2019 

April 26 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA INC - FILES PROSPECTUS RELATED TO POSSIBLE RESALE FROM TIME TO TIME OF UP TO 1.6 MILLION SHARES OF COMMON STOCK - SEC FILING.  Full Article

Azurrx Biopharma Entered Note Purchase Agreement With Adec Private Equity Investments On Feb 14
Wednesday, 20 Feb 2019 

Feb 20 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA - ENTERED NOTE PURCHASE AGREEMENT PURCHASE AGREEMENT WITH ADEC PRIVATE EQUITY INVESTMENTS ON FEB 14 - SEC FILING.  Full Article

Azurrx Biopharma Announces Proposed Public Offering Of Common Stock
Tuesday, 1 May 2018 

April 30 (Reuters) - AzurRx BioPharma Inc ::AZURRX BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AZURRX BIOPHARMA INC - INTENDS TO USE PROCEEDS FROM OFFERING FOR EXPENSES ASSOCIATED WITH AZURRX'S CONTINUING CLINICAL DEVELOPMENT & TESTING OF MS1819.  Full Article

AzurRx Biopharma files for mixed shelf offering of up to $10 mln
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma Inc files for mixed shelf offering of up to $10 million - SEC filing‍​.  Full Article

Azurrx Biopharma, Mayoly Spindler announce IMPD submission
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Azurrx Biopharma Inc ::Azurrx Biopharma and Mayoly Spindler announce MS1819-SD investigational medicinal product dossier (IMPD) submission.Azurrx Biopharma - ‍IMPD submitted via European Medicines Agency clinical trial portal for approval prior to opening of clinical centers in France.  Full Article

AzurRx BioPharma files for stock shelf of upto $10 mln
Thursday, 12 Oct 2017 

Oct 11 (Reuters) - Azurrx Biopharma Inc :Azurrx biopharma inc files for stock shelf of upto $10 million - sec filing‍​‍​.  Full Article

AzurRx Biopharma announces positive MS1819-SD Phase II data in exocrine pancreatic insufficiency
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - AzurRx Biopharma Inc :AzurRx Biopharma and Mayoly-Spindler announce positive MS1819-SD phase II data in exocrine pancreatic insufficiency (epi).AzurRx Biopharma Inc - ‍no serious adverse events or notable mild to moderate events have been reported in open-label, ascending dose phase IIA trial​.AzurRx Biopharma Inc - ‍favorable trends were also observed on other evaluated endpoints​.AzurRx Biopharma Inc - ‍secondary efficacy endpoints are consistently aligning with CFA data and safety profile of MS1819-SD remains favorable​.  Full Article

Azurrx reaches 6th patient enrollment of midstage trial for pancreas drug
Wednesday, 23 Aug 2017 

Aug 23 (Reuters) - Azurrx Biopharma Inc :Azurrx reaches 6th patient enrollment of Phase IIA trial of MS1819 for treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis.Azurrx Biopharma Inc- ‍results on first six patients expected in September from phase IIA trial of MS1819​.Azurrx Biopharma Inc- added additional clinical trial site to further support enrollment in study and other planned future studies.  Full Article

Azurrx Biopharma enters into sublicense agreement with Transchem
Saturday, 12 Aug 2017 

Aug 11 (Reuters) - Azurrx Biopharma Inc -:Azurrx Biopharma Inc - ‍on August 7, 2017, Azurrx Biopharma, Inc entered into a sublicense agreement with Transchem, Inc. - sec filing​.Azurrx Biopharma- ‍transchem granted co exclusive license to patents,patent apps related to helicobacter pylori 5'-methylthioadenosine nucleosidase inhibitors​.  Full Article